SK Bio Announces 100,000 Patients Have Been Treated with Cenobamate
SEOUL, South Korea and KING OF PRUSSIA, Pa., Oct. 12, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology, and its U.S. R&D subsidiary, Proteovant Therapeutics, presented data showing that selectively degrading the epigenetic protein p300, with minimal impact on its paralog CBP, results in suppression of androgen receptor signaling and inhibition of tumor growth in a mouse model of androgen receptor (AR) positive prostate cancer. Findings are being presented today at the American Association for Cancer Research (AACR), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) International Conference on Molecular Targets and Cancer Therapeutics being held in Boston.
SEOUL, South Korea and KING OF PRUSSIA, Pa., Sept. 26, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology, and its U.S. R&D subsidiary, Proteovant Therapeutics, today announced they will present data on the discovery and characterization of a selective IKZF2 molecular glue degrader with best-in-class potential, and on MOPED™, a novel platform for the discovery of molecular glues, at the 20th Annual Discovery on Target Conference being held in Boston, September 25-28, 2023.
London-based Hikma Pharmaceuticals PLC has announced a new strategic partnership and exclusive licensing agreement with South Korean firm SK Biopharmaceuticals, a global biotech company focused on the development of treatments for central nervous system (CNS) disorders and oncology, for the Middle East and North Africa (MENA).
SEOUL, South Korea, Aug. 2, 2023 /PRNewswire/ -- SK Biopharmaceuticals, a global biotech company, announced the formation of its Scientific Advisory Board (SAB), comprising of five prominent experts in oncology, epilepsy, and radiopharmaceutical therapy.
PANGYO, South Korea, Dec. 8, 2022 /PRNewswire/ -- SK Biopharmaceuticals, an innovative global pharmaceutical company, announced that its European partner Angelini Pharma, an international pharmaceutical company part of the privately held Italian Angelini Industries, has launched cenobamate in France.
PANGYO, South Korea, Dec. 4, 2022 /PRNewswire/ -- Seoul National University Bundang Hospital (SNUBH) presented its preliminary study result of seizure monitoring for patients with epilepsy using SK Biopharmaceuticals' multimodal wearable device at the American Epilepsy Society (AES) Annual Meeting 2022 in Nashville, Tennessee, December 2-6. This is the first study of the wearable device developed by SK Biopharmaceuticals, an innovative global pharmaceutical company.
SK Biopharmaceuticals, Co., Ltd. announced that Health Canada has accepted Paladin Labs Inc.'s filing of a New Drug Submission (NDS) for cenobamate...